Based in Madrid, Spain, ProAlt develops non-invasive screening tests and monoclonal antibodies for the efficient monitoring and treatment of colon, breast, and melanoma metastatic tumors. Their main priority is developing a screening test for early diagnosis of colorectal cancer that requires only a conventional blood extraction, offering higher detection capacity, simple usage, and reduced costs compared to invasive tests like colonoscopy. ProAlt also offers custom-tailored services in protein and antibody design and manufacturing, with a deep knowledge of protein and antibody development and production.